Change search
ReferencesLink to record
Permanent link

Direct link
Avidity characterization of genetically engineered T-cells with novel and established approaches
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Ridgeview Instruments AB, Vange, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science. Ridgeview Instruments AB, Vange, Sweden..
Show others and affiliations
2016 (English)In: BMC Immunology, ISSN 1471-2172, E-ISSN 1471-2172, Vol. 17, 23Article in journal (Refereed) PublishedText
Abstract [en]

Background: Adoptive transfer of genetically engineered autologous T-cells is becoming a successful therapy for cancer. The avidity of the engineered T-cells is of crucial importance for therapy success. We have in the past cloned a T-cell receptor (TCR) that recognizes an HLA-A2 (MHC class I)-restricted peptide from the prostate and breast cancer- associated antigen TARP. Herein we perform a side-by-side comparison of the TARP-specific TCR (TARP-TCR) with a newly cloned TCR specific for an HLA-A2-restricted peptide from the cytomegalovirus (CMV) pp65 antigen. Results: Both CD8(+) T-cells and CD4(+) T-cells transduced with the HLA-A2-restricted TARP-TCR could readily be detected by multimer analysis, indicating that the binding is rather strong, since binding occured also without the CD8 co-receptor of HLA-A2. Not surprisingly, the TARP-TCR, which is directed against a self-antigen, had weaker binding to the HLA-A2/peptide complex than the CMV pp65-specific TCR (pp65-TCR), which is directed against a viral epitope. Higher peptide concentrations were needed to achieve efficient cytokine release and killing of target cells when the TARP- TCR was used. We further introduce the LigandTracer technology to study cell-cell interactions in real time by evaluating the interaction between TCR-engineered T-cells and peptide-pulsed cancer cells. We were able to successfully detect TCR-engineered T-cell binding kinetics to the target cells. We also used the xCELLigence technology to analyzed cell growth of target cells to assess the killing potency of the TCR-engineered T-cells. T-cells transduced with the pp65 - TCR exhibited more pronounced cytotoxicity, being able to kill their targets at both lower effector to target ratios and lower peptide concentrations. Conclusion: The combination of binding assay with functional assays yields data suggesting that TARP- TCR-engineered T-cells bind to their target, but need more antigen stimulation compared to the pp65-TCR to achieve full effector response. Nonetheless, we believe that the TARP- TCR is an attractive candidate for immunotherapy development for prostate and/or breast cancer.

Place, publisher, year, edition, pages
2016. Vol. 17, 23
Keyword [en]
T-cell receptor, Affinity, Avidity, LigandTracer, xCELLigence, HLA binding, TARP, CMV pp65
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:uu:diva-300454DOI: 10.1186/s12865-016-0162-zISI: 000379892000001PubMedID: 27411667OAI: oai:DiVA.org:uu-300454DiVA: diva2:951499
Funder
Swedish Cancer SocietySwedish Research Council
Available from: 2016-08-09 Created: 2016-08-09 Last updated: 2016-08-09Bibliographically approved

Open Access in DiVA

fulltext(1822 kB)22 downloads
File information
File name FULLTEXT01.pdfFile size 1822 kBChecksum SHA-512
8e2ddf0bb6e06d92f1fa67008541f513c346a84e85721f17e1109ec6db7b6794a007084f9c1f02135fa32ba576fb8e6fadc280fa9b87beac12d35f2a2d3a220f
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hillerdal, VictoriaAndersson, KarlEssand, Magnus
By organisation
Clinical ImmunologyMedical Radiation Science
In the same journal
BMC Immunology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 22 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 46 hits
ReferencesLink to record
Permanent link

Direct link